Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 1/2011

01-03-2011 | Case Report

Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer

Authors: P. Forde, C. Murphy, C. O’Sullivan, D. Carney

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2011

Login to get access

Abstract

Introduction

Description of the cutaneous side effects of erlotinib.

Materials

Report with images of a single case.

Methods

Case report and review of the literature.

Conclusion

Erlotinib is associated with significant cutaneous toxicity which should be recognised and managed appropriately.
Literature
1.
Shepherd FA, Rodrigues Pereira J, Seymour L et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132CrossRefPubMed
2.
Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23(22):5235–5246CrossRefPubMed
3.
Carser JE, Summers YJ (2006) Trichomegaly of the eyelashes after treatment with erlotinib in non-small-cell lung cancer. J Thorac Oncol 1(9):1040–1041CrossRefPubMed
4.
Gerber PA, Homey B (2008) Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 358(11):1175CrossRefPubMed
5.
Costa DB, Kobayashi S, Schumer ST (2007) Erlotinib-associated alopecia in a lung cancer patient. J Thorac Oncol 2(12):1136–1138CrossRefPubMed
6.
Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425–1433CrossRefPubMed
7.
Metadata
Title
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer
Authors
P. Forde
C. Murphy
C. O’Sullivan
D. Carney
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2011
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-009-0458-6

Other articles of this Issue 1/2011

Irish Journal of Medical Science (1971 -) 1/2011 Go to the issue

Brief Report

Saikosaponins: a potential treatment option for systemic lupus erythematosus

Original Article

Outside the high-volume unit: survival in an 11-year cohort of colorectal cancer patients

Original Article

A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers

Original Article

Why do patients change their general practitioner? Suggestions on corrective actions

Original Article

Is simple nephrectomy truly simple? Comparison with the radical alternative

Original Article

Three generations of matrilineal excess of birth defects in Irish families with neural tube defects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits